Maintenance of response and predictive factors of 1-year GalcanezumAb treatment in real-life migraine patients in Italy: The multicenter prospective cohort GARLIT study.
Vernieri F, Brunelli N, Marcosano M, Aurilia C, Egeo G, Lovati C, Favoni V, Perrotta A, Maestrini I, Rao R, d'Onofrio L, Finocchi C, Aguggia M, Bono F, Ranieri A, Albanese M, Di Piero V, Cevoli S, Altamura C, Barbanti P; GARLIT Study Group.
Vernieri F, et al. Among authors: cevoli s.
Eur J Neurol. 2023 Jan;30(1):224-234. doi: 10.1111/ene.15563. Epub 2022 Sep 26.
Eur J Neurol. 2023.
PMID: 36097739
Free PMC article.